Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia-Reference-Cited by-同舟云学术

Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia

Published:2017-03 Issue:3 Volume:27 Page:83-88
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Hess Mark W.,de Baaij Jeroen H.F.,Broekman Mark M.T.J.,Bisseling Tanya M.,Haarhuis Bertram J.T.,Tan Adriaan C.I.T.L.,te Morsche René H.M.,Hoenderop Joost G.J.,Bindels René J.M.,Drenth Joost P.H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference30 articles.

1. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies;Cheungpasitporn;Ren Fail,2015

2. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis;Park;PLoS One,2014

3. Systematic review: hypomagnesaemia induced by proton pump inhibition;Hess;Aliment Pharmacol Ther,2012

4. Magnesium in man: implications for health and disease;De Baaij;Physiol Rev,2015

5. Proton pump inhibitors and severe hypomagnesaemia;Cundy;Curr Opin Gastroenterol,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of intestine-specific TRPM6 knockout C57BL/6 J mice: effects of short-term omeprazole treatment;Pflügers Archiv - European Journal of Physiology;2024-09-13

2. Genetic drivers of age-related changes in urinary magnesium excretion;Physiological Genomics;2024-09-01

3. A Case of Severe Proton Pump Inhibitor-Induced Hypomagnesemia Refractory to Continuous Oral and Intravenous Magnesium Replenishment;Cureus;2024-02-19

4. Editorial: Exploration of genetic variation, drug response, and interactions between gastrointestinal disorders and other diseases;Frontiers in Pharmacology;2023-09-13

5. Osmotic Demyelination Syndrome in a Normonatremic Patient Under Treatment With Proton Pump Inhibitors;Cureus;2023-08-31